Department of Anesthesiology, Washington University School of Medicine, Campus Box 8054, St Louis, MO, 63110, USA.
CNS Drugs. 2022 May;36(5):483-516. doi: 10.1007/s40263-022-00914-4. Epub 2022 May 5.
Central neuropathic pain is caused by a disease or lesion of the brain or spinal cord. It is difficult to predict which patients will develop central pain syndromes after a central nervous system injury, but depending on the etiology, lifetime prevalence may be greater than 50%. The resulting pain is often highly distressing and difficult to treat, with no specific treatment guidelines currently available. This narrative review discusses mechanisms contributing to central neuropathic pain, and focuses on pharmacological approaches for managing common central neuropathic pain conditions such as central post-stroke pain, spinal cord injury-related pain, and multiple sclerosis-related neuropathic pain. Tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, and gabapentinoids have some evidence for efficacy in central neuropathic pain. Medications from other pharmacologic classes may also provide pain relief, but current evidence is limited. Certain non-pharmacologic approaches, neuromodulation in particular, may be helpful in refractory cases. Emerging data suggest that modulating the primary afferent input may open new horizons for the treatment of central neuropathic pain. For most patients, effective treatment will likely require a multimodal therapy approach.
中枢性神经痛由大脑或脊髓的疾病或损伤引起。中枢神经系统损伤后哪些患者会发展为中枢痛综合征难以预测,但根据病因,终生患病率可能大于 50%。由此产生的疼痛常常非常痛苦且难以治疗,目前尚无特定的治疗指南。本综述讨论了导致中枢性神经痛的机制,并重点介绍了管理常见中枢性神经痛疾病的药物治疗方法,如中风后中枢性疼痛、脊髓损伤相关疼痛和多发性硬化相关神经痛。三环类抗抑郁药、5-羟色胺去甲肾上腺素再摄取抑制剂和加巴喷丁类药物对中枢性神经痛有一定的疗效。来自其他药物类别的药物也可能有止痛作用,但目前证据有限。某些非药物治疗方法,特别是神经调节,对难治性病例可能有帮助。新出现的数据表明,调节初级传入输入可能为中枢性神经痛的治疗开辟新的前景。对于大多数患者,有效的治疗可能需要采用多模式治疗方法。